Lepu Medical expands global reach with licensing deal, adjusts capital

Lepu Medical Technology (Beijing) announced its subsidiary, Shanghai Minwei Biotechnology, entered a licensing agreement with Danish company Sidera Bio Aps for its MWN105 injectable, a GLP-1/GIP/FGF21 receptor triple agonist. Sidera Bio will gain exclusive global rights (excluding Greater China) for development and commercialization.

As part of the deal, Shanghai Minwei will acquire a 9.99% equity stake in Sidera Bio and receive upfront and milestone payments totaling $35m, with potential future milestone payments up to $1.01bn, plus tiered sales royalties. MWN105 is currently undergoing clinical trials in China, with approvals received in November 2024 and March 2025.

In a related development, Lepu Medical completed the cancellation of 37,215,700 repurchased shares on October 30, 2025, reducing its total share capital from 1,880,612,067 shares to 1,843,396,367 shares. This action resulted in China Shipbuilding Industry Corporation 725 Research Institute's stake passively increasing from 12.98% to 13.24%, triggering a 1% integer multiple change.

Concurrently, the company announced an adjustment to the conversion price of its "Lepu Convertible Bond 2." Effective November 3, 2025, the conversion price will be adjusted from CNY 27.63 per share to CNY 27.86 per share, following the share buyback cancellation.